

entry of the Paper Copy of the Sequence Listing into the specification is provided above.

Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

In re application of: Kenneth Walsh  
Application No.: 09/590,740  
Filed: June 8, 2000  
For: HMG COA REDUCTASE INHIBITORS FOR PROMOTING ANGIOGENESIS  
Group No.: 1651  
Examiner: Jon P. Weber

Pursuant to 37 C.F.R. § 1.821(g), Applicants' attorney hereby states that the CRF transferred corresponds exactly to the Paper Copy of the Sequence Listing provided herewith. Applicants' attorney further hereby states that the contents of the Paper Copy of the Sequence Listing and CRF do not go beyond the disclosure in the Application as filed and do not introduce new matter.

Applicants believe that additional fees are not required for consideration of the within Preliminary Amendment. However, if for any reason a fee is required, a fee paid is inadequate or credit is owed for any excess fee paid, you are hereby authorized and requested to charge Deposit Account No. 04-1105.

Respectfully submitted,

Date: November 14, 2003

By:   
Dianne M. Rees, Ph.D.  
(Reg. No. 45,281)  
EDWARDS & ANGELL, LLP  
Intellectual Property Group  
PO BOX 9169  
Boston, MA 02209  
Telephone: 617-439-4444  
Fax: 617-439-4170

Customer No: 21,874